

Sharda Cropchem Limited



ISO 9001: 2015 Reg. No: 702949
CIN: L51909MH2004PLC145007

Tel.: +91 22 66782800
FAX : +91 22 66782828 / 66782808
E-mail : office@shardaintl.com
Regd. Office : Prime Business Park, Dashrathlal Joshi Road, Vile Parle (W),
Mumbai - 400056, India.
www.shardacropchem.com



21st October, 2022

To,

National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051	BSE Limited Phiroze Jeejeebhoi Tower, Dalal Street, Mumbai – 400 001
Trading Symbol: SHARDACROP	Scrip Code: 538666

Subject: Investors / Analyst's Presentation for the quarter & half year ended 30th September, 2022:

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we are enclosing herewith the presentation to be made to the Investors/Analysts on the Financial Results of the Company for the quarter & half year ended 30th September, 2022.

The presentation is also being uploaded on the website of the Company www.shardacropchem.com in accordance with Regulation 46 of the Listing Regulations.

We request you to take the same on record.

Yours Sincerely,

Jetkin Gudhka
Company Secretary &
Compliance Officer

Encl.: As above





Sharda Cropchem Limited



**EXPLORE...
EMERGE...
ENHANCE**

Investor Presentation

October 2022

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Sharda Cropchem Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.



About Sharda Cropchem Limited

“We are a fast-growing global agrochemicals company with a peer position in the generic crop protection chemicals industry. Our vast and growing library of dossiers and IPRs provide us solid foundations for growth in the global marketplace, especially in Advanced Markets such as Europe, North America and Latin America. It equips us with the ability to operate in a diversified range of formulations and generic active ingredients space globally”



Intellectual Property (IP) driven company engaged in marketing and distribution of wide range formulations and generic active ingredients



Asset Light Business Model

Efficiently channelizing time and resources for strengthening core competency of identifying generic molecules and registration opportunities which offer scalable growth with limited capital requirements



Large Pipeline of Registrations*

Procured 2,753 registrations. Additionally, it has filed 1,118 applications for registrations globally pending at different stages



Diversified Sourcing Arrangements

Enduring relationship with multiple manufacturers and formulators enables to source and supply formulations or generic active ingredients at competitive prices



Consistently Increasing Global Presence

With diversified range of product portfolio, Company has grown by expanding business operations in 80+ countries, across Europe, NAFTA, Latin America and ROW



Widespread Distribution Network

Presence in the entire agrochemical value chain with 500 third party distributors and 400+ sales force serving the Company's esteemed clientele in 80+ countries

Company's apt domain knowledge and experience gives substantial competitive advantage for expanding business in existing markets and new geographies

Asset Light Business Model

Overall Agrochemical Value Chain

Sharda's Operating Area



SHARDA CROPCHEM'S ASSET LIGHT BUSINESS MODEL

Focus on identification of generic molecules, preparing dossiers, seeking registrations, marketing & distributing formulations through third party distributors and/or own sales force

Manufacturing of AIs and formulations is outsourced

Highly flexible operating model resulting in

- Overall cost competitiveness
- Efficient management of fluctuating market demand across various geographies
- Offering wide range of formulations and AIs

Acts as a key differentiator from an innovator company, allowing the Company to save its capital, time and resources on R&D

Increasing Global Presence having a Widespread Distribution



Presence
80+ countries

across Europe, NAFTA,
LATAM & RoW

Sales Force
400+

Distributors
500+

CAPEX incurred in H1 FY23*
Rs. 230 Cr.



Over the years, we've built a strong brand franchise within our global markets; we are benefiting through the economies of scale in our portfolio and leveraging value of our supply chain to deliver value to our customers across geographies

Company has gained a great deal from globalization, including new customers and diverse geocentric revenue streams. Over the years, we have mastered flexibility and adopted innovative ways to grow our business overseas

In addition to newer markets, the wide global presence has allowed us to find new, specialised sales and local marketing talent.

Successfully adopted a factory-to-farmer approach to become a one-stop solution provider to our global customers

Strengthening and widening the sales force in Europe, USA, Canada, Mexico, Colombia, South Africa, India, and rest of the world, in addition to third party distributors with a goal to enhance its presence in the agrochemical value chain

It enables the Company to penetrate its formulations and generic active ingredients in various countries backed by the third-party distributors and presence of its own sales force



* Plus related revenue expenditure on registrations



THE SHARDA ADVANTAGE

Global Reach

Wide Product Range

Healthy relationships with suppliers

Quality with Affordability

Faster Sales Service

One Stop Solution Provider for Crop Care Products

Way Forward

Forward Integration - Build Sales Force

- Leverage market presence and execution capabilities
- Adopt the factory to farmer approach and be a one stop solution provider
- Strategy on ground in different regions of NAFTA, Europe, LATAM and other key markets in ROW

Expand & Strengthen Distribution Presence


- Expand geographical reach using existing library of dossiers
- Two-fold strategy of further penetrating existing markets and entering new markets

Continual Investment in Product Registrations

- Continue to identify generic molecules going off patent
- Investing in preparing dossiers and seeking registrations in own name


Focus on Operational Efficiencies

- Accelerated focus on revenue generating investments
- Margin improvements
- Better cost management and eliminate NVAs



Industry Outlook and Growth Drivers

Global crop protection chemicals market value (In Billion USD) – CAGR of 3.5%



INDUSTRY DRIVERS

1

A growing population: the global population is set to **increase by 1.2 billion by 2030 and 2 billion by 2050**, while the middle class will more than double to 4.9 billion by 2030




2

A growing middle class fuels demand for increased food and protein production, **which in turn drives demand for grain to support growth**



3

Fewer arable acres per capita means that products need to continue to maximise farmer yields; **arable land is expected to decrease from half an acre per person today to less than one-third of an acre per person by 2050**



Mr. Ramprakash V. Bubna
Chairman & Managing Director

- Holds a Bachelor's Degree of Technology in Chemical Engineering from IIT, Bombay
- He has over 53 years of experience in chemicals, agrochemicals and related businesses
- He is responsible for the Company's overall business operations and strategy



Mr. Ashish Bubna
Whole Time Director

- Holds a Bachelor's Degree in Commerce from the University of Mumbai
- Over 30 years of experience in marketing of chemicals, agrochemicals and related businesses.
- Instrumental in strategizing early investment in product registrations and building the library of product dossiers.
- Responsible for marketing, procurement, registrations and logistics functions of the agrochemical business.



Mr. Manish Bubna
Whole Time Director

- Holds a Bachelor's Degree in Chemical Engineering from the Department of Chemical Technology, Bombay University.
- Over 28 years of experience in chemicals, agrochemicals and related businesses
- Spearheaded the Company's foray into the conveyor belt and general chemicals business
- Also oversees the information technology, logistics and documentation functions of the Company



Mr. Ashok Vashisht
Chief Financial Officer

- He is Fellow member of Chartered Institute of Management Accountants UK & accredited CGMA, Fellow member of CPA Australia, Fellow member of The Institute of Cost Accountants of India and Associate member of The ICSI. He has also done DipIFR from ACCA UK and qualified Independent Director from IICA
- 25+ years of rich professional corporate experience in global and Indian MNCs in the field of Strategy, M&A, Financial Management, Direct & Indirect Taxation, Strategic Cost Management, Project Management, Statutory Audits & Internal Audits, Governance & Risk Management



Q2 FY23 Financial Highlights

Q2 FY23: Segment Wise Highlights

₹ Cr.

Agrochemical Segment

Non Agrochemical Segment

TOTAL REVENUES

78%

80%





22%

20%

% of Revenue

100%

100%



+14%

+4%

+12%


Q2 FY23: Product Wise Highlights (Agrochemical Segment)

₹ Cr.


Herbicides		Insecticides		Fungicides		% of Revenue		TOTAL REVENUES (Agrochemical Segment)	
52%	57%	32%	22%	16%	21%	100%	100%		





↑ +25%



↓ -22%



↑ +50%




↑ 14%


Q2 FY23: Region Wise Breakup (Agrochemical Segment)

₹ Cr.


Europe




NAFTA Region




TOTAL REVENUES (Agrochemical Segment)



LATAM Region



RoW




% of Revenue


Q2 FY23: Region Wise Breakup (Non Agrochemical Segment)

₹ Cr.

Europe




NAFTA Region




TOTAL REVENUES


(Non - Agrochemical Segment)



LATAM Region



RoW




 % of Revenue

Q2 FY23: Financial Highlights

₹ Cr.


Revenues & GP Margin



Revenue growth led by better product mix & price realization


Gross Margins have been impacted by weakening of €/€ leading to increased input cost

EBITDA & EBITDA Margin*




EBITDA and Margin impacted due to lower GP Margins, general inflation and strengthening of global workforce to support future growth

Profit After Tax & PAT Margin



PAT was impacted by increased forex losses of Rs. Rs. 38.7 crores in Q2 FY23

Profit After Tax & PAT Margin (Excluding Forex Impact)



Excluding Forex Loss, PAT has grown by 12% due to revenue growth, product mix & increased efficiencies


* Excluding

1. Other expenses of Rs 1.79 Crs. towards loss on fair valuation of investments during quarter ended September 30, 2022 as against gain of Rs.2.25 Crs. for corresponding quarter ended September 30, 2021 which has been included under Other Income

2. EBITDA is excluding IA & IAUD write-off (Rs. 1.5 cr. in Q2 FY23; Rs. 0.9 cr. in Q2 FY22 ; IA & IAUD – Intangible Assets & Intangible Assets Under Development)

Impact of weakened Euro to the Dollar in the last six months


USD / Euro Price Chart



Major currencies have depreciated to the USD in the last six months due to the ongoing war between Russia & Ukraine

Over 45% of H1 FY23 Sales from Agrochemical business have been to the Europe whereas majority of the Company's Raw Material is imported from China and payments are done in US Dollar

This has impacted the Company's Gross Margin and overall profitability as the Euro had considerably depreciated against the dollar



MEASURES TAKEN BY COMPANY

- Increased sales focus on NAFTA region
- Sourcing in Euro currency
- Optimal Hedging of currencies
- Seeking Price increase to minimize this forex impact



H1 FY23 Financial Highlights

H1 FY23 Segment Wise Highlights

Agrochemical Segment

82%

77%

Non Agrochemical Segment

18%


23%

% of Revenue


TOTAL REVENUES

100%



100%



↑ +15%




↑ +56%



↑ +22%

H1 FY23: Product Wise Highlights (Agrochemical Segment)


₹ Cr.




H1 FY23: Region Wise Breakup (Agrochemical Segment)

₹ Cr.


Europe




NAFTA Region




TOTAL REVENUES (Agrochemical Segment)



LATAM Region



RoW




% of Revenue


H1 FY23: Region Wise Breakup (Non Agrochemical Segment)

₹ Cr.

Europe




NAFTA Region




TOTAL REVENUES



(Non - Agrochemical Segment)



LATAM Region



RoW




 % of Revenue

H1 FY23: Financial Highlights

₹ Cr.


Revenues & GP Margin



Revenue growth led by better product mix & price realization


Gross Margins have been impacted by weakening of €/€ leading to increased input cost

EBITDA & EBITDA Margin*




EBITDA and Margin impacted due to lower GP Margins, general inflation and strengthening of global workforce to support future growth

Profit After Tax & PAT Margin



PAT was impacted by increased forex losses of Rs. Rs. 81.9 crores in H1 FY23

Profit After Tax & PAT Margin (Excluding Forex Impact)



Excluding Forex Loss, PAT has grown by 62% due to revenue growth, product mix & increased efficiencies


* Excluding

1. Other expenses of Rs 13.94 Crs. towards loss on fair valuation of investments during half year ended September 30, 2022 as against gain of Rs.3.52 Crs. for corresponding half year ended September 30, 2021 which has been included under Other Income


2. EBITDA is excluding IA & IAUD write-off (Rs. 4.3 cr. in H1 FY23; Rs. 4.4 cr. in H1 FY22 ; (IA & IAUD – Intangible Assets & Intangible Assets Under Development)

Strong Balance Sheet


Working Capital (in Days)



RoCE



RoE



Total Equity

Rs. 1,930 crores

Rs. 1,912 crores as on Mar'22

Total Debt

Rs. 17 crores

Rs. 38 crores as on Mar'22

Cash & Cash Equivalents

Rs. 283 crores

Rs. 300 crores as on Mar'22



Annexure

Q2 & H1 FY23 Financial Highlights



Sharda Cropchem Limited

₹ Cr.

Particulars	Q2 FY23	Q2 FY22	Y-o-Y	H1 FY23	H1 FY22	Y-o-Y
Revenue from Operations	721.5	642.8	12%	1,546.0	1,265.5	22%
COGS	524.4	462.9		1,139.5	903.1	
Gross Profit	197.1	179.8		406.5	362.4	
Gross Margin %	27.3%	28.0%		26.3%	28.6%	
Employee Expenses	8.6	10.5		17.0	20.6	
Other Expenses	84.9	66.4		189.7	135.8	
EBITDA*	107.0	103.8	3%	218.1	210.4	4%
EBITDA Margin %	14.8%	16.1%		14.1%	16.6%	
Forex (Gain)/Loss	38.6	13.2		81.9	1.7	
Depreciation	60.4	60.6		115.1	114.6	
Other Income	10.2	12.9		30.5	19.3	
EBIT	14.9	42.0		33.3	109.0	
EBIT Margin %	2.1%	6.5%		2.2%	8.6%	
Finance Cost	0.4	0.4		1.1	1.0	
PBT	14.5	41.5		32.2	108.0	
Tax Expense	2.5	9.5		-2.5	37.9	
PAT	12.1	32.0	-62%	34.7	70.1	-50%
PAT Margin %	1.7%	5.0%		2.2%	5.5%	
Earnings Per Share (EPS) In Rs.	1.34	3.55		3.85	7.77	
PAT (Excluding Forex Impact)	50.7	45.2	12%	116.6	71.8	62%
PAT Margin % (Excluding Forex Impact)	7.0%	7.0%		7.5%	5.7%	

* Excluding Other expenses of Rs 1.79 Crs. towards loss on fair valuation of investments during quarter ended September 30, 2022 as against gain of Rs.2.25 Crs. for corresponding quarter ended September 30, 2021 which has been included under Other Income. Excluding Other expenses of Rs 13.94 Crs. towards loss on fair valuation of investments during half year ended September 30, 2022 as against gain of Rs.3.52 Crs. for corresponding half year ended September 30, 2021 which has been included under Other Income

* EBITDA is excluding IA & IAUD write-off (Rs. 1.5 cr. in Q2 FY23; Rs. 0.9 cr. in Q2 FY22 ; Rs. 4.3 cr. in H1 FY23; Rs. 4.4 cr. in H1 FY22

On Consolidated Basis

Balance Sheet - Consolidated




EQUITY & LIABILITIES	Sept-22	Mar-22
Equity		
Equity share capital	90.2	90.2
Other equity	1,840.4	1,822.2
Equity attributable to equity holders of the Company	1,930.6	1,912.4
Non-controlling interests	0.3	0.3
Total Equity	1,930.9	1,912.7
Non-current liabilities		
Financial liabilities		
Lease liabilities	1.3	3.5
Trade payables		
total outstanding dues of micro enterprises and small enterprises		0.0
other than micro enterprises and small enterprises		2.4
Other financial liabilities	1.7	1.6
Provisions	2.4	2.3
Deferred tax liabilities (net)	123.3	128.9
Total non-current liabilities	128.7	138.7
Current liabilities		
Financial liabilities		
Borrowings	17.0	38.0
Lease liabilities	4.8	5.1
Trade payables		
total outstanding dues of micro enterprises and small enterprises	4.7	8.8
other than micro enterprises and small enterprises	719.3	1,168.8
Other financial liabilities	414.8	324.8
Other current liabilities	39.1	55.4
Provisions	90.1	86.7
Income Tax Provisions	3.5	4.2
Total current liabilities	1,293.3	1,691.8
Total Equity & Liabilities	3,352.9	3,743.2

ASSETS	Sept-22	Mar-22
Non-current assets		
Property, plant and equipment	11.1	14.4
Goodwill	0.0	0.0
Intangible assets	700.1	577.4
Intangible assets under development	199.1	212.2
Financial assets	0.0	0.0
Other Financial Assets	13.5	11.2
Deferred Tax Assets	4.5	4.9
Income tax assets (net)	83.1	71.6
Total non-current assets	1,011.4	891.7
Current assets		
Inventories	965.5	892.8
Financial assets		
Investments	75.0	134.4
Trade receivables	999.9	1,540.0
Cash and cash equivalents	97.9	56.7
Bank balance other than cash and cash equivalents	110.2	109.3
Loans	0.0	0.5
Other financial assets	24.9	48.9
Other current assets	68.1	68.9
Total current assets	2,341.5	2,851.5
Total Assets	3,352.9	3,743.2


Key Financial Performance Indices

₹ Cr.


Revenue




EBITDA & EBITDA Margin*




Profit After Tax & PAT Margin




RoCE



RoE



Net Cash & Cash Equivalents^



* EBITDA is excluding IA & IAUD write-off

^ Total Cash & Cash Equivalents - Debt

Historical Profit & Loss



Sharda Cropchem Limited

₹ Cr.

Particulars	FY22	FY21	FY20	FY19	FY18
Revenue from Operations	3,579.8	2,395.6	2,003.0	1,997.6	1,706.6
COGS	2,499.8	1,636.0	1,388.8	1,387.3	1,143.7
Gross Profit	1,080.0	759.7	614.3	610.2	562.8
Gross Margin %	30.2%	31.7%	30.7%	30.5%	33.0%
Employee Expenses	44.2	37.3	34.9	33.5	33.5
Other Expenses	336.4	305.5	282.4	250.1	183.9
EBITDA*	728.6	455.2	351.7	368.8	353.3
EBITDA Margin %	20.4%	19.0%	17.6%	18.5%	20.7%
Forex (Gain)/Loss	16.5	-19.9	15.1	4.5	-8.5
Depreciation	245.3	170.4	137.1	99.4	69.9
Other Income	28.9	45.9	42.1	20.6	8.1
EBIT	466.5	312.2	186.8	243.4	292.1
EBIT Margin %	13.0%	13.0%	9.3%	12.2%	17.1%
Finance Cost	2.2	2.8	1.9	8.4	4.9
PBT	464.2	309.5	184.9	235.0	287.2
Tax Expense	115.0	80.2	20.2	58.7	96.4
PAT	349.3	229.2	164.7	176.3	190.8
PAT Margin %	9.8%	9.6%	8.2%	8.8%	11.2%
Earnings Per Share (EPS) In Rs.	38.71	25.40	18.25	19.55	21.15

* EBITDA is excluding IA & IAUD write-off

Balance Sheet - Equity & Liabilities



Sharda Cropchem Limited

₹ Cr.

Equities & Liabilities	FY22	FY21	FY20	FY19	FY18
Shareholder's Funds					
Equity and Share Capital	90.2	90.2	90.2	90.2	90.2
Other Equity	1,822.2	1,524.1	1,312.6	1,193.7	1,044.6
Non-controlling Interest	0.3	0.3	0.3	0.2	0.2
Total Equity	1,912.8	1,614.6	1,403.1	1,284.1	1,135.0
Non-Current Liabilities					
Borrowings	-	-	0.1	0.1	0.1
Trade Payables	2.4	2.4	2.4	2.9	3.0
Lease Liabilities	3.5	8.4	-	-	-
Other Financial Liabilities	1.6	3.2	13.1	1.4	0.3
Provisions	2.3	3.0	2.7	2.2	2.1
Deferred Tax Liabilities (net)	128.9	92.9	69.3	91.0	83.1
Total Non-Current Liabilities	138.6	109.9	87.5	97.6	88.6
Current Liabilities					
Borrowings	38.0	67.8	0.0	0.0	169.6
Lease Liabilities	5.1	4.5	-	-	-
Trade Payables	1,177.6	806.8	686.7	636.2	633.8
Other Financial Liabilities	324.8	149.1	89.7	104.0	106.2
Other Current Liabilities	55.4	58.0	54.4	60.7	56.1
Current Tax Liabilities	4.2	3.2	1.5	0.6	24.0
Provisions	86.7	50.0	24.4	20.1	12.9
Total Current Liabilities	1,691.8	1,139.4	856.7	821.7	1,002.6
Total Equity & Liabilities	3,743.1	2,863.9	2,347.2	2,203.3	2,226.2

Balance Sheet - Assets



Sharda Cropchem Limited

₹ Cr.

ASSETS	FY22	FY21	FY20	FY19	FY18
Assets					
Non-Current Assets					
Property, Plant and Equipment	14.4	20.9	27.8	13.5	10.7
Goodwill	0.0	0.4	0.4	0.4	0.4
Other Intangible assets	577.4	523.1	388.1	357.8	215.2
Intangible assets under development	212.2	131.0	161.4	219.8	359.9
Deferred Tax Assets (net)	4.9	6.0	3.9	5.5	40.0
Non-Current Tax Assets	71.6	73.6	72.5	49.2	29.3
Other financial assets	11.2	9.4	11.6	8.9	7.3
Total Non-Current Assets	891.7	764.5	665.7	655.2	662.9
Current Assets					
Inventories	892.8	525.5	382.2	364.9	530.4
Investments	134.4	83.0	115.5	211.9	22.1
Trade Receivables	1,540.0	1,162.6	988.4	811.4	891.9
Cash & Cash equivalents	56.7	85.6	77.8	50.6	61.3
Other Bank balances	109.3	175.0	75.7	73.0	39.3
Loans	0.5	-	-	-	-
Other Financial Assets	48.9	28.1	11.3	11.9	0.0
Other Current Assets	68.9	39.6	29.6	24.3	18.3
Total Current Assets	2,851.5	2,099.3	1,681.5	1,548.2	1,563.3
Total Assets	3,743.1	2,863.9	2,347.2	2,203.3	2,226.2

CSR initiatives taken up by the Company are in the areas of Promoting Education, Healthcare, Eradicating Hunger, Empowerment of Women, Animal Welfare, Promotion of Sports and Rural Development Projects

Promoting Education



Animal Welfare



Medical Aid & Relief

'मरीजों की देखभाल सच्चा परमार्थ' राज्यपाल कोश्यारी ने युवाओं में बढ़ते नशा पर जताई चिंता

■ प्रसं, मुंबई : राज्यपाल भगत सिंह कोश्यारी ने मरीजों की देखभाल को सच्चा परमार्थ बताते हुए कहा कि अगर लोग टीबो के मरीजों को गोद ले और देश को टीबी मुक्त बनाने के लिए मरीजों के पोषण आहार के खर्च का वहन करें, तो यह भी दान होगा। इस दौरान उन्होंने युवाओं में तंबाकू के साथ नशे की बढ़ती प्रवृत्ति पर चिंता जताई। वह परमार्थ रत्न पुरस्कार समारोह में बोल रहे थे।

सामाजिक संस्था परमार्थ सेवा समिति की तरफ से राजभवन में आयोजित पुरस्कार और दीपावली स्नेह कार्यक्रम का आयोजन किया गया था। इसमें राज्यपाल के हाथों टाटा मेमोरियल अस्पताल के निदेशक डॉ. राजेंद्र बडवे और उप निदेशक डॉ. शैलेश श्रीखंडे को कैसर के इलाज, सर्जरी और अनुसंधान में उनके उल्लेखनीय कार्य के लिए परमार्थ रत्न पुरस्कार से सम्मानित किया गया। साथ ही, अविनाश सावले को परमार्थ खेल रत्न पुरस्कार से सम्मानित किया गया। समारोह में राजश्री बिरला विशिष्ट अतिथि थी।

शहरीकरण के साथ बढ़ रहा कैसर: डॉ. राजेंद्र बडवे ने कहा कि भारत



में कैसर की दर पश्चिमी देशों की तुलना में कम है, यह संतोष की बात है। लेकिन, देश में बढ़ते शहरीकरण के साथ कैसर की दर बढ़ रही है। अगर 2035 तक तंबाकू की खेती पूरी तरह से बंद कर दी जाए, तो बड़े पैमाने पर कैसर को नियंत्रित किया जा सकता है, क्योंकि कुल कैसर रोगियों में से तंबाकू के सेवन से होने वाले कैसर रोगियों की संख्या 40 प्रतिशत है। संस्था अध्यक्ष मनमोहन गोयनका ने संस्था की ओर से किए जा रहे कार्यों की रूपरेखा

रखी। संस्था के चेयरमैन लक्ष्मीनारायण वियानी ने IS मॉडल कोमोथेरेपी सेंटर टाटा मेमोरियल हॉस्पिटल को बनाकर दान में देने की घोषणा की। इस अवसर पर महिला समिति की अध्यक्ष शारदा रामप्रकाश बुवना, बजरंगलाल तापड़िया, महावीरप्रसाद तापड़िया, ज्योतिप्रसाद तापड़िया, दिलीप पिरामल, रवि लालपुरिया, कैलाश अग्रवाल, रमेश पोद्दार सहित बड़ी संख्या में लोग उपस्थित थे।



EXPLORE...EMERGE...ENHANCE

THANK YOU

Company: Sharda Cropchem Limited



Sharda Cropchem Limited

CIN: L67120MH1995PLC086696

Mr. Ashok Vashisht - CFO

cfo@shardaintl.com

Tel: +91 22 6678 2800

Investor Relation Advisors: Strategic Growth Advisors Pvt. Ltd.

SGA Strategic Growth Advisors

CIN: U74140MH2010PTC204285

Mr. Deven Dhruva / Mr. Karan Parekh

deven.dhruva@sgapl.net / karan.parekh@sgapl.net

Tel: +91 98333 73300 / +91 74983 98940